IBRX Stock Jumps on Progress in NK Cell Therapy Production

Core Insights - Shares of ImmunityBio (IBRX) increased by over 7% following the completion of two manufacturing engineering programs for its autologous memory cytokine-enhanced natural killer (M-ceNK) cell therapy platform [1][4] - The successful completion of the NK2022 and NK2023 programs demonstrates the ability to safely and consistently produce M-ceNK cells at scale [1][6] Manufacturing and Safety - ImmunityBio conducted apheresis collections in 64 subjects, including healthy donors and cancer patients, with no serious adverse events reported [2] - A single apheresis collection can yield up to 5 billion NK cells, sufficient for generating 8 to 10 treatment doses per patient within 12 days [3][6] - The company administered a total of 23 doses to 10 cancer patients, successfully demonstrating repeat dosing and cryo-banking of M-ceNK cells without serious adverse events [3][8] Clinical Development - ImmunityBio completed a phase I dose-escalation study of M-ceNK cells combined with Anktiva in 10 patients with relapsed or refractory solid tumors, reporting no serious adverse events [8] Stock Performance - Year to date, shares of ImmunityBio have surged over 300%, significantly outperforming the industry growth of 3% [5]